Clinical Trial Update: Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus [Phase 2]

View source ↗

Summary

A Phase 2 trial of temsirolimus in patients with recurrent uterine sarcoma or uterine carcinosarcoma was terminated; results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Carcinosarcoma
• Uterine Sarcoma

Drugs mentioned

• Temsirolimus (temsirolimus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Uterine Sarcoma, Uterine Carcinosarcoma | Phase 2 | Status: TERMINATED | Results posted: 2016-11-09